Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer’s Disease
Year: 2010
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease (AD). The pathobiological changes related to AD occur long before the overt clinical symptoms. The plasma lipid peroxidation enzyme F2-isoprostane has been suggested as a biomarker to detect the progression from mild cognitive impairment (MCI) to AD. OBJECTIVE: To test whether plasma and urine F2-isoprostane was diagnostic for dementia in living people. METHODS: Plasma and urine were collected from 222 Religious Orders Study participants with a clinical diagnosis of no cognitive impairment, MCI or AD at time of fluid collection. Isoprostane levels were determined using gas chromatography/mass spectroscopy. RESULTS: Plasma and urine F2-isoprostane levels did not differ between the three clinical groups. Postmortem neuropathologic diagnosis of subjects who died during the course of the study was not associated with baseline blood or plasma F2-isoprostane levels. CONCLUSIONS: In living people, plasma or urine isoprostane levels were not sensitive enough to discriminate between individuals with a clinical diagnosis of no cognitive impairment, MCI or AD.
Source: Neurodegenerative Diseases
DOI: 10.1159/000289224
Authors: Elliott J. Mufson, Sue Leurgans
Institution: Rush University Medical Center
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2086923544